Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,663,800.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.32, for a total transaction of $1,624,800.00.
• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $103.38, for a total transaction of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $107.12, for a total transaction of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total value of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00.

Moderna Price Performance

Moderna stock traded down $0.59 during trading hours on Friday, hitting $125.00. 4,512,362 shares of the stock were exchanged, compared to its average volume of 4,144,759. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79. The stock has a market capitalization of $47.86 billion, a P/E ratio of -10.07 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The business’s 50-day moving average is $104.47 and its two-hundred day moving average is $94.14.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. During the same quarter in the previous year, the business earned $0.19 EPS. The business’s quarterly revenue was down 91.0% compared to the same quarter last year. Equities research analysts expect that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on MRNA. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Thursday. Royal Bank of Canada increased their price objective on Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Friday. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Canaccord Genuity Group boosted their target price on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $129.55.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Moderna by 22.6% in the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after buying an additional 6,248,623 shares during the last quarter. Wellington Management Group LLP increased its holdings in Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after purchasing an additional 1,614,460 shares during the period. The Manufacturers Life Insurance Company raised its position in Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after purchasing an additional 1,690,341 shares during the last quarter. Norges Bank acquired a new position in Moderna during the 4th quarter worth about $347,565,000. Finally, Invesco Ltd. grew its position in shares of Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after buying an additional 517,683 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.